NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$296.7m

Last Updated

2021/04/17 00:23 UTC

Data Sources

Company Financials +

Executive Summary

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Fortress Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: FBIO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-24.3%

FBIO

3.3%

US Biotechs

1.3%

US Market


1 Year Return

84.8%

FBIO

22.3%

US Biotechs

53.9%

US Market

Return vs Industry: FBIO exceeded the US Biotechs industry which returned 26.6% over the past year.

Return vs Market: FBIO exceeded the US Market which returned 57.5% over the past year.


Shareholder returns

FBIOIndustryMarket
7 Day-24.3%3.3%1.3%
30 Day0%-1.2%3.3%
90 Day22.3%-4.7%8.9%
1 Year84.8%84.8%24.1%22.3%56.6%53.9%
3 Year-1.9%-1.9%32.5%25.9%64.4%53.6%
5 Year1.2%1.2%44.5%33.0%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is Fortress Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fortress Biotech undervalued compared to its fair value and its price relative to the market?

3.9x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FBIO is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.8x).


Future Growth

How is Fortress Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

56.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FBIO's revenue (28.8% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: FBIO's revenue (28.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Fortress Biotech performed over the past 5 years?

1.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.5% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: FBIO has a negative Return on Equity (-52.28%), as it is currently unprofitable.


Financial Health

How is Fortress Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: FBIO's short term assets ($261.6M) exceed its short term liabilities ($48.0M).

Long Term Liabilities: FBIO's short term assets ($261.6M) exceed its long term liabilities ($83.9M).


Debt to Equity History and Analysis

Debt Level: FBIO's debt to equity ratio (32.7%) is considered satisfactory.

Reducing Debt: FBIO's debt to equity ratio has increased from 27.5% to 32.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: FBIO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 22.4% each year.


Dividend

What is Fortress Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Lindsay Rosenwald (65 yo)

7.33yrs

Tenure

US$1,090,016

Compensation

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Executive Chairman, Chief Executive Officer and President o...


CEO Compensation Analysis

Compensation vs Market: Lindsay's total compensation ($USD1.09M) is about average for companies of similar size in the US market ($USD1.56M).

Compensation vs Earnings: Lindsay's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FBIO's management team is seasoned and experienced (7.3 years average tenure).


Board Members

Experienced Board: FBIO's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: FBIO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.


Top Shareholders

Company Information

Fortress Biotech, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fortress Biotech, Inc.
  • Ticker: FBIO
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$296.662m
  • Shares outstanding: 94.91m
  • Website: https://www.fortressbiotech.com

Number of Employees


Location

  • Fortress Biotech, Inc.
  • 2 Gansevoort Street
  • 9th Floor
  • New York
  • New York
  • 10014
  • United States

Listings


Biography

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 00:23
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.